Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Óscar Arrieta(Instituto Nacional de Cancerología), Kumar Prabhash(Tata Memorial Hospital), Konstantinos N. Syrigos(Sotiria General Hospital), Tuncay Göksel(Ege University), Keunchil Park(Sungkyunkwan University), Vera Gorbunova(Russian Cancer Research Center NN Blokhin), Rubén Dario Kowalyszyn, Joanna Pikiel(Centrum Onkologii), Grzegorz Czyżewicz(John Paul II Hospital), С. В. Орлов(First Pavlov State Medical University of St. Petersburg), C. Lewanski(Charing Cross Hospital), Michael Thomas(German Center for Lung Research), Paolo Bidoli(Azienda Ospedaliera San Gerardo), Shaker R. Dakhil(Cancer Center of Kansas), Steven Gans, Joo-Hang Kim(Yonsei University Health System), Alexandru Grigorescu(Institutul Oncologic Bucuresti), Nina Karaseva(City Clinical Oncology Center), Martin Reck(German Center for Lung Research), Federico Cappuzzo(Ospedale di Livorno), Ekaterine Alexandris(Eli Lilly (United States)), Andreas Sashegyi(Eli Lilly (United States)), Sergey Yurasov(Eli Lilly (United States)), M. Pérol(Centre de Recherche en Cancérologie de Lyon)
Cited by 1,304Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis